In a report released today, Sean McGowan from Roth MKM maintained a Buy rating on Niagen Bioscience, with a price target of $23.00. The company’s shares closed yesterday at $7.26.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, McGowan is a 4-star analyst with an average return of 9.4% and a 45.21% success rate.
In addition to Roth MKM, Niagen Bioscience also received a Buy from H.C. Wainwright’s Ram Selvaraju in a report issued today. However, on October 2, TR | OpenAI – 4o downgraded Niagen Bioscience (NASDAQ: NAGE) to a Hold.
The company has a one-year high of $14.69 and a one-year low of $3.18. Currently, Niagen Bioscience has an average volume of 1.13M.
Read More on NAGE:
Disclaimer & DisclosureReport an Issue
- Niagen Bioscience Raises 2025 Sales Outlook Amid FDA Ruling
- Fifth Third buying Comerica, AMD gets OpenAI boost: Morning Buzz
- Niagen Bioscience raises FY25 revenue view to up 25%-30% from up 22%-27%
- Niagen Bioscience’s Niagen IV, injections now available at iCRYO clinics
- Promising Growth and Innovation Drive Buy Rating for Niagen Bioscience
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
/AI%20(artificial%20intelligence)/Data%20Center%20by%20Caureem%20via%20Shutterstock%20(2).jpg)
/PayPal%20Holdings%20Inc%20HQ%20photo-by%20bennymarty%20via%20iStock.jpg)
/Micron%20Technology%20Inc_%20logo%20on%20building-by%20vzphotos%20vis%20iStock.jpg)